A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome

NCT03053271 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

INDUSTRY

Sponsor class

Stopped Slow enrollment

Conditions

Cushing Syndrome

Interventions

DRUG: ATR-101
DRUG: Placebo

Sponsor

Millendo Therapeutics US, Inc.